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Loss-of-Function Alanyl-tRNA Synthetase Mutations
Cause an Autosomal-Recessive Early-Onset Epileptic
Encephalopathy with Persistent Myelination Defect
Cas Simons,1,17 Laurie B. Griffin,2,3,17 Guy Helman,4 Gretchen Golas,5 Amy Pizzino,4 Miriam Bloom,6
Jennifer L.P. Murphy,4 Joanna Crawford,1 Sarah H. Evans,7 Scott Topper,8 Matthew T. Whitehead,9
John M. Schreiber,4 Kimberly A. Chapman,10,11 Cyndi Tifft,5 Katrina B. Lu,12 Howard Gamper,12
Megumi Shigematsu,12 Ryan J. Taft,1,13,14 Anthony Antonellis,2,15,16 Ya-Ming Hou,12,18
and Adeline Vanderver3,11,14,18,*
Mutations in genes encoding aminoacyl-tRNA synthetases are known to cause leukodystrophies and genetic leukoencephalopathies—
heritable disorders that result in white matter abnormalities in the central nervous system. Here we report three individuals (two siblings
and an unrelated individual) with severe infantile epileptic encephalopathy, clubfoot, absent deep tendon reflexes, extrapyramidal
symptoms, and persistently deficient myelination on MRI. Analysis by whole exome sequencing identified mutations in the nuclear-
encoded alanyl-tRNA synthetase (AARS) in these two unrelated families: the two affected siblings are compound heterozygous for
p.Lys81Thr and p.Arg751Gly AARS, and the single affected child is homozygous for p.Arg751Gly AARS. The two identified mutations
were found to result in a significant reduction in function. Mutations in AARS were previously associated with an autosomal-dominant
inherited form of axonal neuropathy, Charcot-Marie-Tooth disease type 2N (CMT2N). The autosomal-recessive AARSmutations identi-
fied in the individuals described here, however, cause a severe infantile epileptic encephalopathy with a central myelin defect and
peripheral neuropathy, demonstrating that defects of alanyl-tRNA charging can result in a wide spectrum of disease manifestations.Advances in next-generation sequencing have reduced
the number of unsolved cases in genetic leukoencephalo-
pathies and leukodystrophies; however, many still remain
a diagnostic mystery. Mutations in genes encoding
aminoacyl-transfer RNA (tRNA) synthetases have received
increased attention in individuals with white-matter ab-
normalities on MRI due to the recent identification of a se-
ries of related diseases involving these enzymes. Mutations
in the majority of tRNA synthetases (22 of 37) and many
tRNA synthetase cofactors have been implicated in human
disease (Table S1),1–15 and of these, mutations in eight loci
(DARS [MIM 615281], RARS [MIM 616140], AIMP1 [MIM
260600], AARS2 [MIM 615889], DARS2 [MIM 611105],
EARS2 [MIM 614924], LARS2 [MIM 615300], MARS2
[MIM 611390], FARS2 [MIM 614946]) have been
implicated in leukodystrophies or leukoencephalopa-
thies.2,8,9,13,14,16–18 Aminoacyl-tRNA synthetases are ubiq-
uitously expressed, essential enzymes responsible for
charging tRNA molecules with cognate amino acids—the
first step of protein translation. These enzymes are present
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The Amingly, certain tRNA synthetases have non-canonical func-
tions in biological processes such as angiogenesis, regula-
tion of gene transcription, and RNA splicing.19 These
non-canonical tRNA synthetase functions are conserved
across the complete phylogeny of animals and are now
established as playing key roles in a number of pathophys-
iological processes.19
Here we report three individuals with remarkably similar
clinical presentations and biallelic loss-of-function muta-
tions in alanyl-tRNA synthetase (AARS [MIM 601065]).
The clinical presentations of these individuals include
severe infantile epileptic encephalopathy with myoclonic
seizures and extrapyramidal features, peripheral neuropa-
thy based on absent peripheral reflexes, congenital vertical
tali, and neuroradiologic features consistent with persis-
tently deficient myelination. Our functional analyses
reveal that the identified mutations reduce aminoacyla-
tion activity, thus implicating AARS mutations in an auto-
somal-recessive early infantile epileptic encephalopathy.
To date, AARS mutations have been implicated only
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Table 1. Summary of Key Clinical Features of Affected Individuals
LD_0115.0A LD_0115.0B LD_0857.0
Nucleotide variants c.242A>C, c.2251A>G c.242A>C, c.2251A>G c.2251A>G
Protein variants p.Lys81Thr, p.Arg751Gly p.Lys81Thr, p.Arg751Gly p.Arg751Gly
Status compound heterozygous compound heterozygous homozygous
Intrauterine growth retardation yes no yes
Age at presentation 36 weeks GA 3 months birth
Congenital vertical tali yes yes yes
Failure to thrive yes yes yes
Microcephaly << 4 SD below the norm << 4 SD below the norm << 4 SD below the norm
Refractory myoclonic epilepsy onset at 2 months onset at 3 months onset at 6 months
Spasticity yes yes yes
Chorea/adventitious movement blepharospasm, orobuccal
dyskinesia, dystonia of
limbs, chorea
blepharospasm, orobuccal
dyskinesia, dystonia of
limbs, chorea
blepharospasm, orobuccal
dyskinesia, dystonia of
limbs, chorea
Loss of peripheral deep tendon reflexes yes yes yes
Abbreviation is as follows: GA, gestational age.(CMT2N [MIM 613287]), an axonal peripheral neuropathy
characterized by muscle weakness, wasting, and impaired
sensation in the extremities.20,21 Thus, our findings
broaden the genetic and clinical spectrum associated
with AARS mutations.
The three affected individuals and their families were
collected prospectively as part of the Myelin Disorders Bio-
registry Project (MDBP) and the NIHUndiagnosed Diseases
Program with approval from the institutional review
boards at Children’s National Health System and the
National Human Genome Research Institute, respectively.
Written informed consent was obtained for each study
participant including specific informed consent for
whole exome sequencing (WES). Genomic DNA samples
were collected from blood samples provided to the
biorepository.
The clinical features of each individual are summarized
in Table 1 and full clinical descriptions are provided in
the Supplemental Data case reports. LD_0115.0A and
LD_0115.0B are sibling of mixed-European descent with
a history of hypomyelinating leukoencephalopathy,
epileptic encephalopathy with congenital vertical tali,
microcephaly, failure to thrive, and developmental delay.
On examination the children had severe encephalopathy,
extrapyramidal symptoms including blepharospasm, spas-
ticity, and absent peripheral reflexes. Both siblings are
similarly affected, although LD_0115.0A, the elder of the
sibling pair, is more severely affected.
LD_0857.0 is of mixed European descent and is unre-
lated to the siblings described above. He presented after a
full-term birth with intrauterine growth retardation,
abnormal movements characterized as dystonia and trem-
ulousness, microcephaly, and congenital vertical tali. In
the first months of life, he developed progressive micro-676 The American Journal of Human Genetics 96, 675–681, April 2, 2cephaly, failure to thrive, refractory myoclonic epilepsy,
feeding difficulties, and nystagmus. On examination he
also had severe encephalopathy, extrapyramidal symp-
toms including blepharospam, spasticity, and absent pe-
ripheral reflexes. LD_0857.0 is the most severely affected
of the three children and has been critically ill numerous
times, requiring mechanical ventilation. He is currently
dependent on nasal BiPAP support for home pulmonary
care.
EEGs were obtained in the newborn period for
LD_0115.0A and LD_0857.0 and were indicative of mild
encephalopathy with excessive sharp waves seen in the
central-temporal areas. Later recordings in all three sub-
jects demonstrated moderate diffuse background slowing
(or suppression in LD_0857.0) with multifocal posterior-
predominant interictal epileptiform discharges, typically
polyspike, and slow-wave discharges or high-amplitude
occipital paroxysmal fast (beta) activity (Figure S1). In
one individual (LD_0115.0B), routine EEG performed
at age 5 months showed multiple tonic extensor spasms
associated with a generalized electrodecrement, but no
hypsarrhythmia.
Several brain MRI findings were common among all
three individuals (Figure 1). A relentlessly progressive
diffuse cerebral atrophy affects both gray andwhite matter,
evolving from mild to severe with onset in the first
few weeks of life. Early scans from LD_0115.0A and
LD_0857.0 performed on days 0 and 27, respectively,
showed normal brain volume. Slow progression of mild
to moderate generalized brainstem and cerebellar volume
loss was present in all individuals. Posterior fossa volume
loss commenced after the initiation of cerebral volume
loss, no earlier than 2 to 8 months of age. A progressive
micro-encephaly was consequent.015
Figure 1. MRI Findings in Individuals
with AARS Mutations
(A–D) Sagittal T1-weighted images show
varying degrees of parenchymal volume
loss (B–D) manifesting different degrees
of thinning of the corpus callosum,
enlarged sulci/fissures, and ventriculome-
galy along with relative hypointensity of
the corpus callosum reflecting hypomyeli-
nation. Cerebral volume was normal in
LD_0857.0 at day 0 (A) with progressive
cerebral atrophy, severe at 14 months (B).
The vermis evolved from being hypoplas-
tic (A) to atrophic (B) and the brain-
stem showed no interval growth (B).
LD_0115.0A (C) had moderate cerebral
atrophy and mild cerebellar volume loss
by 14 months, and LD_0115.0B (D) had
mild cerebral and cerebellar volume loss
at 17 months. Disproportionate lateral
ventriculomegaly reflects superimposed
hydrocephalus from prior intraventricular
hemorrhage (D).
(E–H) Axial T2-weighted images demon-
strate variable degrees of cerebral volume
loss/atrophy (F–H) and hypomyelination
(E–H). Generalized, excessive-for-age white
matter hyperintensity reflects hypomyeli-
nation. At birth, the normal hypointense
PLIC signal is not visible in LD_0857.0
(E). By 14 months, only mild myelination
progress has occurred with myelination
similar to that of a normal 3 month old;
the optic radiations and PLIC are now
hypointense. Similar findings are present at 14 months in LD_0115.0A (G) and 17 months in LD_0115.0B (H).
(I) Axial DWI image from LD_0857.0 at 14 months shows hyperintense signal consistent with restricted diffusion and myelin edema
in the optic radiations (arrows) and superior cerebellar peduncle decussations (arrowhead). Similar myelin edema was present in the
occipitofrontal fascicles, central tegmental tracts, and globi pallidi (not shown).
(J) SV MRS (144 ms echo time) over the left basal ganglia reveals elevation of citrate at 2.6 ppm (arrowhead), glycine at 3.5 ppm (long
arrow), and creatine at 3 ppm and 3.9 ppm (short arrows).Hypomyelination was universal, present in all individ-
uals, and clinically suspected on all exams from day 0 to
30 months, but was not formally diagnosed until follow-
up MRI was performed at 12 months. A slow myelin pro-
gression occurred in all individuals without normalization
up to at least 30 months. Myelination progressed to no
more than the degree expected for a normal 6-month-old
subject. Cerebellar and brainstem myelination ranged
from normal to mildly decreased. All individuals had evi-
dence of prior choroid plexus hemorrhage in the lateral
ventricular glomus. One individual (LD_0115.0B) had a
chronic non-communicating hydrocephalus probably sec-
ondary to intraventricular hemorrhage causing cerebral
aqueduct adhesions.
WES was performed on all affected individuals and their
parents as part of a cohort of 70 families diagnosed with
unresolved leukodystrophies recruited to the MDBP. How-
ever, prior to exome sequencing, the three individuals were
subgrouped within the broader cohort on the basis of their
phenotypic homogeneity. Exome capture and sequencing
was performed at the Queensland Centre for Medical
Genomics with either Illumina Nextera Rapid Capture or
the SeqCap EZ Human Exome Library v.3.0 kits withThe Amcaptured libraries sequenced with the Illumina platform.
Reads were aligned to the reference human genome
(GRCh37) and pedigree-informed variant calling was per-
formed with the Real Time Genomics (RTG) integrated
analysis tool rtgFamily v.3.2.22 All variants were annotated
with SnpEff v.3.423 and filtered to include SNPs and indels
predicted to result in altered mRNA splicing or protein
sequence. Rare variants were identified on the basis of a
MAF < 0.01 in both the NHLBI Exome Sequencing Project
(ESP) Exome Variant Server and 1000 Genomes database
(October 2013). Subsequent identification and prioritiza-
tion of candidate variants was performed with an in-house
workflow incorporating the annotated variant data and
segregation within each pedigree.
Analysis of the exomes revealed that all three affected in-
dividuals carry rare, biallelicmissense variants inAARSwith
no other compelling pathogenic variants common to the
two families (Figure 2). The affected siblings LD_0115.0A
and LD_0115.0B are compound heterozygous carriers of
two AARS missense mutations. The maternally inherited
mutation (RefSeq accession number NM_001605.2;
c.242A>C [p.Lys81Thr]) is not present in the dbSNP
v.141, 1000 Genomes, NHLBI ESP6500, or Exomeerican Journal of Human Genetics 96, 675–681, April 2, 2015 677
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Figure 2. Pathogenic Mutations in Hu-
man AARS
(A) The p.Lys81Thr mutation and
p.Arg751Gly mutations mapped to the
known functional domains of human
AARS, showing the aminoacylation
domain, the tRNA recognition domain,
the editing domain, and the C-terminal
domain.
(B) Multiple-species sequence alignment of
AARS showing the p.Lys81Thr mutation
and p.Arg751Gly mutation along with
the flanking protein sequences in multiple
and evolutionarily diverse species.
(C) Structure of an E. coli alanyl-tRNA syn-
thetase in complex with alanine analog.26
Arrow indicates the conserved residue
homologous to human p.Lys81.
(D) Structure of archaea A. fulgidus alanyl-
tRNA synthetase in complex with tRNA
and an alanine analog.24 Arrow indicates
the conserved residue homologous to hu-
man p.Arg751.
In (C) and (D), the AARS domains are
colored as shown in (A).Aggregation Consortium (ExAC) databases and is predicted
to be damaging by both SIFT (score: 0.000) and PolyPhen2
(score: 1.00). The paternally inherited mutation (RefSeq
NM_001605.2; c.2251A>G [p.Arg751Gly]) is present in
dbSNP (rs143370729)—however, from a cohort of more
than 60,000 individuals, the ExAC project identified only
six heterozygous carriers of this allele, giving an allele fre-
quency of less than 0.00005 in this predominantly Euro-
pean population. This mutation is also predicted to be
damagingbyboth SIFT (score: 0.000) andPolyPhen2 (score:
1.00). The third affected individual LD_0857.0 is homozy-
gous for the same p.Arg751Gly mutation identified in the
LD_0115 siblings. Neither the p.Lys81Thr nor p.Arg751Gly
missense mutations were detected in any other individuals
in an in-house control dataset of more than 350 exomes.
AARS consists of four highly conserved functional do-
mains: the aminoacyl-tRNA synthetase domain (residues
1–254), the tRNA recognition domain (residues 255–451),
the editing domain (residues 468–757), and the C-terminal
domain (residues 758–968) (Figure 2).24 The p.Lys81Thr
variant affects a lysine residue that resides in the amino-
acyl-tRNA synthetase domain, whereas the p.Arg751Gly
variant affects an arginine residue localized in the AARS ed-
iting domain (Figure 2A). Both residues are highly evolu-
tionarily conserved: p.Lys81 is conserved in animals, yeast,
and bacteria, and p.Arg751 is also strictly conserved in
archaea (Figure 2B).678 The American Journal of Human Genetics 96, 675–681, April 2, 2015AARS catalyzes the aminoacylation
of tRNAAla with alanine in a reaction
dependent on ATP. The majority of
disease-associated mutations in ami-
noacyl-tRNA synthetases, including
those in AARS associated with
CMT2N, have been shown to impairaminoacylation activity.20,21 We tested the ability of
p.Lys81Thr and p.Arg751Gly mutant AARS to catalyze
aminoacylation in vitro compared to wild-type AARS by
monitoring incorporation of tritium-labeled alanine onto
in vitro transcribed tRNAAla. Steady-state assays for amino-
acylation showed that the wild-type enzyme displayed
Km (tRNA) and kcat values similar to those reported previ-
ously, showing a kcat/Km value of 0.13 5 0.04 mM
1s1
(Table 2).21 The p.Lys81Thr mutant was mildly defective,
due to a 2-fold increase in Km (tRNA) with no change in
kcat, leading to an overall 2-fold decrease in kcat/Km.
In contrast, the p.Arg751Gly mutant was more severely
defective, showing both a 2-fold increase in Km (tRNA)
and a 5-fold decrease in kcat, leading to an overall 10-fold
decrease in kcat/Km. Thus, both mutations impaired the
aminoacylation activity of AARS in vitro. The p.Arg751Gly
mutation is localized within the AARS editing domain,
so we also investigated the impact of this variant on edit-
ing activity; however, there was no detectable effect of
the mutation on editing function (Figure 3).
To further assess the functional consequences of
p.Lys81Thr and p.Arg751Gly in AARS in vivo, we modeled
each mutation in the yeast ortholog ALA1 and compared
the ability of mutant and wild-type ALA1 to support yeast
cell growth in a haploid yeast strain with the endogenous
ALA1 deleted.21 The wild-type ALA1 vector rescued
yeast viability, whereas the empty vector was unable to
Table 2. Aminoacylation Kinetics of AARS Variants
Km (mM) kcat (s
1) kcat/Km (mM
1s1)
Ratio
to WT
WT 3.15 0.7 0.4 5 0.1 0.13 5 0.04 1
p.Lys81Thr 6.05 1.8 0.4 5 0.1 0.07 5 0.03 1/2
p.Arg751Gly 6.35 1.4 0.07 5 0.03 0.010 5 0.005 1/10
Steady-state assays of aminoacylation of tRNAAla with 3H-alanine (20 mM) were
performed at 37C with each enzyme at 20 nM, tRNAAla in varying concentra-
tions (0.6–16 mM) in a buffer containing 20 mM KCl, 50 mM HEPES (pH 7.5),
4.0 mM DTT, 0.2 mg/ml BSA, 10 mM MgCl2, and 2 mM ATP. Error bars show
standard deviations derived from averaging at least four independent sets of
experiments. Wild-type and mutants of human AARS were constructed in
pET-DEST42 gateway vector (Life Technologies) for expression in E. coli with
a 63 His C-terminal fusion tag. Protein was purified with the Co2þ-affinity resin
was achieved according to the manufacturer’s protocol (Novagen). Human
tRNAAla was prepared and purified and annealed as described.1,2 Steady-state
aminoacylation assays were performed as described, monitoring incorporation
of 3H-Ala (specific activity of 16,500 dpm/pmole) to the synthesis of 3H-Ala-
tRNAAla as acid precipitable counts on filter pads.1 Each reaction was initiated
by addition of an AARS enzyme (20 nM) to a mixture of increasing concentra-
tions of tRNAAla (0.6–16 mM). Acid precipitable counts were corrected for the
filter quench factor and were calculated as pmoles of 3H-Ala-tRNAAla. Data were
fit to the Michaelis-Menten equation. Figure 3. Analysis of the Hydrolytic Editing Activity of AARS
Deacylation of the incorrectly charged Ser-tRNAAla was monitored
over time by the wild-type enzyme (black) and the p.Arg751Gly
mutant (red). The uncatalyzed deacylation reaction (the no-
enzyme reaction, indicated in blue) was run in parallel as a control
for background hydrolysis. Values represent the average of two in-
dependent experiments and error bars show the standard devia-
tion. The substrate Ser-tRNAAla for analysis of post-transfer editing
was prepared by 32P-labeling of the QA A76 nucleotide in the tran-
script of human tRNAAla with the CCA enzyme,3 followed by
aminoacylation with chemically synthesized Ser-DBE using the
dFx flexizyme.4,5 Deacylation was monitored in 50 mM HEPES
(pH 7.5), 20 mM KCl, 4 mM DTT, and 10 mM MgCl2 at 37
C
with 5 nM of WT or p.Arg751Gly human AARS and a mixture of
2.8 mM Ser-tRNAAla and 17.2 mM tRNAAla. At the indicated time
points, aliquots of a deacylation reaction were quenched with a
buffer containing 200 mM NaOAc (pH 5.0) and treated with S1
nuclease for 20 min at 37C to digest the tRNA to 50-phosphate
mononucleotides. The aliquots were then subjected to thin layer
chromatography through a PEI cellulose matrix with 0.1 M
NH4Cl and 5% acetic acid to separate [
32P]seryl-AMP from [32P]
AMP. Quantification of the two products by a phosphorimager
and analysis of the ratio of (ser-AMP) over (AMP) determined the
extent of Ser-tRNAAla remaining after the editing reaction.complement loss of the endogenous ALA1 allele (Figure 4).
Yeast expressing p.Arg751Gly ALA1 showed survival
comparable to those expressing wild-type ALA1. Yeast ex-
pressing p.Lys81Thr ALA1, however, demonstrated
dramatically reduced, but not ablated, growth (Figure 4),
indicating that p.Lys81Thr AARS represents a hypomor-
phic AARS allele in vivo.
This study has provided insight into the pathogenic
mechanism of the p.Lys81Thr and p.Arg751Gly AARS
mutations identified in three individuals with a phenotyp-
ically identical recessive, early-onset epileptic encephalop-
athy. Modeling of the E. coli crystal structure of AARS24
indicates that the p.Lys81Thr mutation affects a highly
conserved lysine residue (Figure 2B) in a loop adjacent to
the AARS synthetic active site (Figure 2C). The p.Lys81Thr
variant reduced yeast growth in vivo and decreased amino-
acylation activity by 50% in vitro. The p.Arg751Gly
mutation affects a highly conserved arginine residue
(Figure 2B) at the interface with the backbone of the 50
nucleotide in the acceptor stem of tRNAAla when modeled
on the A. fulgidus AARS, possibly playing a role in orienting
the acceptor end for aminoacylation (Figure 2D).24 The
pronounced aminoacylation activity impairment seen for
the p.Arg751Gly mutation, decreasing the kcat/Km value
10-fold, is consistent with the more severe phenotype of
LD_0857.0, who is homozygous for this allele.
The data presented here implicate loss-of-function AARS
mutations in a previously unreported recessive phenotype
of severe epileptic encephalopathy with central myelin
deficits and peripheral neuropathy based on absent periph-
eral reflexes. The severe delay in myelination seen in these
cases is not consistent with classic hypomyelinating leuko-
dystrophies, in which there is typically no progression of
myelination over time. At this point, it is unclear whether
AARSmutations result in a primary defect of myelin devel-The Amopment or whether the delay in myelination can be attrib-
uted to primary neuronal dysfunction.25
It is intriguing to note that two previously reported AARS
missense mutations20,21 cause Charcot-Marie-Tooth type
2N (CMT2N), a dominant axonal peripheral neuropathy
characterized by muscle weakness, wasting, and impaired
sensation in the extremities. These mutations have cata-
strophic effects on AARS activity (50-fold and 4,130-fold
decreases in kcat/Km). This is in stark contrast to the rela-
tively mild 10-fold and 2-fold reduction in aminoacylation
activity associated with the mutations described here. This
suggests a model by which heterozygosity for a variant
that reduces AARS aminoacylation activity below a certain
threshold presents as a dominant peripheral neuropathy,
probably through the compensatory function of the re-
maining wild-type allele. However, carrying two hypomor-
phic AARS alleles results in a more severe overall reduction
in AARS function and causes not only a peripheralerican Journal of Human Genetics 96, 675–681, April 2, 2015 679
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Figure 4. Yeast Complementation Studies
Yeast complementation assays were performed as previously
described.1 Haploid Dala1 yeast strains carrying a wild-type
ALA1 on a URA3-bearing vector were transformed with a LEU2-
bearing vector containing wild-type ALA1, p.Lys85Thr ALA1
(orthologous to human p.Lys81Thr AARS), p.Arg747Gly ALA1 (or-
thologous to human p.Arg751Gly AARS), or no insert (pRS315
Empty). Single colonies from two independent transformations
were grown to saturation in SD -leu-ura liquid media (Teknova)
then spotted (undiluted or diluted 1:10 and 1:100 in H2O) on
plates containing 0.1% 5-fluoroorotic acid (5-FOA) or SD -leu-ura
growth media (Teknova) and incubated at 30C for 48 hr. Survival
was determined by visual inspection of growth. Culture dilutions
are indicated on the left andmedia conditions are indicated on the
right.neuropathy, but also a severe infantile epileptic encepha-
lopathy. In summary, our findings implicate an auto-
somal-recessive phenotype caused by AARS mutations
and reveal a broader-than-previously-appreciated spec-
trum of disorders.Supplemental Data
Supplemental Data include case reports, two figures, and one table
and can be found with this article online at http://dx.doi.org/10.
1016/j.ajhg.2015.02.012.Acknowledgments
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